Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perfumer: PET/CT Directed Treatment Pause in mRCC
NCT07175480Phase 2Recruiting
- Sponsor
- Jinling Hospital
- Start
- Jan 2025
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in metastatic renal cell carcinoma (mRCC), sponsored by Jinling Hospital. Primary endpoint: Progression-free survival rate at 24 months. Started Jan 2025; status: recruiting.
02
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT07175480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07175480.